![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Department of Drug Metabolism, Merck Research Laboratories, Rahway, New Jersey (D.P.H., B.W., S.W.H., R.E., D.C.E.); Rosetta Inpharmatics LLC, Merck Research Laboratories, Kirkland, Washington (X.D., Y.D.H., R.G.U.); and Department of Preclinical Drug Metabolism, Merck Research Laboratories, West Point, Pennsylvania (E.J.C., T.H.R.)
Ligand-mediated activation of the pregnane X receptor (PXR, NR1I2) is postulated to affect both hepatic and intestinal gene expression, because of the presence of this nuclear receptor in these important drug metabolizing organs; as such, activation of this receptor may elicit the coordinated regulation of PXR target genes in both tissues. Induction of hepatic and intestinal drug metabolism can contribute to the increased metabolism of drugs, and can result in adverse or undesirable drug-drug interactions. 2(S)-((3,5-bis(Trifluoromethyl)benzyl)-oxy)-3(S)phenyl-4-((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (L-742694) is a potent activator of the rat PXR and was characterized for its effects on hepatic and intestinal gene expression in female Sprague-Dawley rats by DNA microarray analysis. Transcriptional profiling in liver and small intestine revealed that L-742694 and dexamethasone (DEX) induced the prototypical battery of PXR target genes in liver, including CYP3A, Oatp2, and UGT1A1. In addition, both DEX and L-742694 induced common gene expression profiles that were specific to liver or small intestine, but there was a distinct lack of coordinated gene expression of genes common to both tissues. This pattern of gene regulation occurred in liver and small intestine independent of PXR, constitutive androstane receptor, or hepatic nuclear factor-4
expression, suggesting that other factors are involved in controlling the extent of coordinated gene expression in response to a PXR agonist. Overall, these results suggest that ligand-mediated activation of PXR and induction of hepatic, rather than small intestinal, drug metabolism genes would contribute to the increased metabolism of orally administered pharmaceuticals.
Address correspondence to: Dr. Dylan P. Hartley, Dept. of Drug Metabolism, Merck Research Laboratories, Rahway, NJ 07065. E-mail: dylan_hartley{at}merck.com
This article has been cited by other articles:
|
|
 |
|
  M. H. Court, S. Hazarika, S. Krishnaswamy, M. Finel, and J. A. Williams Novel Polymorphic Human UDP-glucuronosyltransferase 2A3: Cloning, Functional Characterization of Enzyme Variants, Comparative Tissue Expression, and Gene Induction Mol. Pharmacol., September 1, 2008; 74(3): 744 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Miller, B. Bauer, and A. M. S. Hartz Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy Pharmacol. Rev., June 1, 2008; 60(2): 196 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Sane, D. J. Buckley, A. R. Buckley, S. C. Nallani, and P. B. Desai Role of Human Pregnane X Receptor in Tamoxifen- and 4-Hydroxytamoxifen-Mediated CYP3A4 Induction in Primary Human Hepatocytes and LS174T Cells Drug Metab. Dispos., May 1, 2008; 36(5): 946 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Osabe, J. Sugatani, T. Fukuyama, S.-i. Ikushiro, A. Ikari, and M. Miwa Expression of Hepatic UDP-Glucuronosyltransferase 1A1 and 1A6 Correlated with Increased Expression of the Nuclear Constitutive Androstane Receptor and Peroxisome Proliferator-Activated Receptor {alpha} in Male Rats Fed a High-Fat and High-Sucrose Diet Drug Metab. Dispos., February 1, 2008; 36(2): 294 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Deo and S. M. Bandiera Biotransformation of Lithocholic Acid by Rat Hepatic Microsomes: Metabolite Analysis by Liquid Chromatography/Mass Spectrometry Drug Metab. Dispos., February 1, 2008; 36(2): 442 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Alnouti and C. D. Klaassen Regulation of Sulfotransferase Enzymes by Prototypical Microsomal Enzyme Inducers in Mice J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 612 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Dongol, Y. Shah, I. Kim, F. J. Gonzalez, and M. C. Hunt The acyl-CoA thioesterase I is regulated by PPAR{alpha} and HNF4{alpha} via a distal response element in the promoter J. Lipid Res., August 1, 2007; 48(8): 1781 - 1791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Cheng and C. D. Klaassen Regulation of mRNA Expression of Xenobiotic Transporters by the Pregnane X Receptor in Mouse Liver, Kidney, and Intestine Drug Metab. Dispos., November 1, 2006; 34(11): 1863 - 1867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sugatani, T. Wada, M. Osabe, K. Yamakawa, K. Yoshinari, and M. Miwa Dietary Inulin Alleviates Hepatic Steatosis and Xenobiotics-Induced Liver Injury in Rats Fed a High-Fat and High-Sucrose Diet: Association with the Suppression of Hepatic Cytochrome P450 and Hepatocyte Nuclear Factor 4{alpha} Expression Drug Metab. Dispos., October 1, 2006; 34(10): 1677 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ekins, S. Andreyev, A. Ryabov, E. Kirillov, E. A. Rakhmatulin, S. Sorokina, A. Bugrim, and T. Nikolskaya A COMBINED APPROACH TO DRUG METABOLISM AND TOXICITY ASSESSMENT Drug Metab. Dispos., March 1, 2006; 34(3): 495 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Miki, T. Suzuki, K. Kitada, N. Yabuki, R. Shibuya, T. Moriya, T. Ishida, N. Ohuchi, B. Blumberg, and H. Sasano Expression of the Steroid and Xenobiotic Receptor and Its Possible Target Gene, Organic Anion Transporting Polypeptide-A, in Human Breast Carcinoma Cancer Res., January 1, 2006; 66(1): 535 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Aouabdi, G. Gibson, and N. Plant TRANSCRIPTIONAL REGULATION OF THE PXR GENE: IDENTIFICATION AND CHARACTERIZATION OF A FUNCTIONAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR {alpha} BINDING SITE WITHIN THE PROXIMAL PROMOTER OF PXR Drug Metab. Dispos., January 1, 2006; 34(1): 138 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Krasowski, K. Yasuda, L. R. Hagey, and E. G. Schuetz Evolution of the Pregnane X Receptor: Adaptation to Cross-Species Differences in Biliary Bile Salts Mol. Endocrinol., July 1, 2005; 19(7): 1720 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Peterson, J. Bigler, N. K. Horner, J. D. Potter, and J. W. Lampe Cruciferae Interact with the UGT1A1*28 Polymorphism to Determine Serum Bilirubin Levels in Humans J. Nutr., May 1, 2005; 135(5): 1051 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ekins, E. Kirillov, E. A. Rakhmatulin, and T. Nikolskaya A NOVEL METHOD FOR VISUALIZING NUCLEAR HORMONE RECEPTOR NETWORKS RELEVANT TO DRUG METABOLISM Drug Metab. Dispos., March 1, 2005; 33(3): 474 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Bauer, A. M. S. Hartz, G. Fricker, and D. S. Miller Modulation of p-Glycoprotein Transport Function at the Blood-Brain Barrier Experimental Biology and Medicine, February 1, 2005; 230(2): 118 - 127. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
